Evidence map›Paper›PMID 32448787›Full record

ArticleBMJ open diabetes research & care2020

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation.

Andrew P McGovern, Michael Hogg, Beverley M Shields, Naveed A Sattar, Rury R Holman, Ewan R Pearson, Andrew T Hattersley, Angus G Jones, John M Dennis, MASTERMIND consortium

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  11. Review
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Andrew P McGovernUniversity of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, UK a.mcgovern@exeter.ac.uk.ORCID 0000-0002-6833-9399
Michael HoggUniversity of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, UK.
Beverley M ShieldsUniversity of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, UK.ORCID 0000-0003-3785-327X
Naveed A SattarInstitute of Cardiovascular Sciences, University of Glasgow, Glasgow, UK.
Rury R HolmanRadcliffe Department of Medicine, University of Oxford, Oxford, Oxfordshire, UK.ORCID 0000-0002-1256-874X
Ewan R PearsonDivision of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK.
Andrew T HattersleyUniversity of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, UK.
Angus G JonesUniversity of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, UK.
John M DennisUniversity of Exeter Medical School, Institute of Biomedical and Clinical Science, University of Exeter, Exeter, Devon, UK.
MASTERMIND consortium
University of Exeter · GBCardiovascular Institute Hospital · JPUniversity of Dundee · GBUniversity of Oxford · GB

Funding

Medical Research Council MR/N00633X/1Wellcome TrustWellcome Trust 102820/Z/13/Z
6 · The paper itself

Abstract

introductionTo identify risk factors, absolute risk, and impact on treatment discontinuation of genital infections with sodium-glucose co-transporter-2 inhibitors (SGLT2i). RESEARCH DESIGN AND

methodsWe assessed the relationship between baseline characteristics and genital infection in 21 004 people with type 2 diabetes initiating SGLT2i and 55 471 controls initiating dipeptidyl peptidase-4 inhibitors (DPP4i) in a UK primary care database. We assessed absolute risk of infection in those with key risk factors and the association between early genital infection and treatment discontinuation.

resultsGenital infection was substantially more common in those treated with SGLT2i (8.1% within 1 year) than DPP4i (1.8%). Key predictors of infection with SGLT2i were female sex (HR 3.64; 95% CI 3.23 to 4.11) and history of genital infection; <1 year before initiation (HR 4.38; 3.73 to 5.13), 1-5 years (HR 3.04; 2.64 to 3.51), and >5 years (HR 1.79; 1.55 to 2.07). Baseline HbA

conclusionsFemale sex and history of prior infection are simple features that can identify subgroups at greatly increased risk of genital infections with SGLT2i therapy. These data can be used to risk-stratify patients. High HbA

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsFemaleGenitaliaHumansMaleRisk FactorsDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsA1Cadherence to medicationscandidanon-insulin treated type 2 diabetes

Identifiers

PMID32448787
PMCPMC7252998
OpenAlexW3028391295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.